Fangrong Yan

3.5k total citations
108 papers, 1.5k citations indexed

About

Fangrong Yan is a scholar working on Molecular Biology, Statistics and Probability and Cancer Research. According to data from OpenAlex, Fangrong Yan has authored 108 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 33 papers in Statistics and Probability and 23 papers in Cancer Research. Recurrent topics in Fangrong Yan's work include Statistical Methods in Clinical Trials (32 papers), Optimal Experimental Design Methods (18 papers) and Cancer-related molecular mechanisms research (11 papers). Fangrong Yan is often cited by papers focused on Statistical Methods in Clinical Trials (32 papers), Optimal Experimental Design Methods (18 papers) and Cancer-related molecular mechanisms research (11 papers). Fangrong Yan collaborates with scholars based in China, United States and France. Fangrong Yan's co-authors include Xiaofan Lu, Ying Yuan, Liyun Jiang, Yujie Zhou, Jialin Meng, Sumithra J. Mandrekar, Yang Wang, Xinjia Ruan, Yue Zhu and Liya Zhang and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Fangrong Yan

98 papers receiving 1.4k citations

Peers

Fangrong Yan
Dinesh P. de Alwis United States
Alexei Dmitrienko United States
Jin Y. Jin United States
Frank Pétavy Netherlands
Tomoyuki Sugimoto Japan
Robert Gagnon United States
Mark Sale United States
Ji Lin United States
Ivan Nestorov United States
Dinesh P. de Alwis United States
Fangrong Yan
Citations per year, relative to Fangrong Yan Fangrong Yan (= 1×) peers Dinesh P. de Alwis

Countries citing papers authored by Fangrong Yan

Since Specialization
Citations

This map shows the geographic impact of Fangrong Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangrong Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangrong Yan more than expected).

Fields of papers citing papers by Fangrong Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangrong Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangrong Yan. The network helps show where Fangrong Yan may publish in the future.

Co-authorship network of co-authors of Fangrong Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Fangrong Yan. A scholar is included among the top collaborators of Fangrong Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangrong Yan. Fangrong Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Ruitao, et al.. (2024). Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical Trials. 21(3). 308–321. 2 indexed citations
2.
Jiang, Liyun, et al.. (2024). MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities. SHILAP Revista de lepidopterología. 7(3). 159–167.
3.
4.
Jiang, Liyun, Peter F. Thall, Fangrong Yan, Scott Kopetz, & Ying Yuan. (2023). BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials. 20(5). 486–496. 5 indexed citations
5.
Meng, Jialin, Aimin Jiang, Xiaofan Lu, et al.. (2023). Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy. SHILAP Revista de lepidopterología. 2(4). e147–e147. 21 indexed citations
6.
Yan, Fangrong, et al.. (2023). Local continual reassessment methods for dose finding and optimization in drug-combination trials. Statistical Methods in Medical Research. 32(10). 2049–2063. 1 indexed citations
7.
Su, Xiaoping, Xiaofan Lu, Linda Dainese, et al.. (2023). Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors. Nature Communications. 14(1). 7884–7884. 9 indexed citations
8.
Su, Liwen, et al.. (2022). An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022. 1–13. 1 indexed citations
9.
Su, Liwen, et al.. (2022). Bayesian two‐stage sequential enrichment design for biomarker‐guided phase II trials for anticancer therapies. Biometrical Journal. 64(7). 1192–1206. 1 indexed citations
10.
Zhou, Yujie, Xiaofan Lu, Jialin Meng, et al.. (2021). Specific Epigenetic age Acceleration Patterns Among Four Molecular Subtypes of Gastric Cancer and their Prognostic Value. Epigenomics. 13(10). 767–778. 4 indexed citations
11.
Lu, Xiaofan, Jialin Meng, Yujie Zhou, Liyun Jiang, & Fangrong Yan. (2020). MOVICS : an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 36(22-23). 5539–5541. 105 indexed citations
12.
Ruan, Xinjia, Xiaofan Lu, Jun Gao, et al.. (2020). Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment. Journal of Cellular Physiology. 236(2). 1214–1227. 6 indexed citations
13.
Meng, Jialin, Xiaofan Lu, Yujie Zhou, et al.. (2020). Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel‐like factors in prostate cancer. Journal of Cellular and Molecular Medicine. 24(10). 5797–5810. 25 indexed citations
14.
Lin, Ruitao, Yanhong Zhou, Fangrong Yan, Daniel Li, & Ying Yuan. (2020). BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology. 4(4). 1393–1402. 80 indexed citations
15.
Jiang, Liyun, Fangrong Yan, Peter F. Thall, & Xuelin Huang. (2020). Comparing Bayesian early stopping boundaries for phase II clinical trials. Pharmaceutical Statistics. 19(6). 928–939. 7 indexed citations
16.
17.
Liu, Shengjie, et al.. (2019). Bayesian Two-Stage Adaptive Design in Bioequivalence. The International Journal of Biostatistics. 16(1). 5 indexed citations
18.
Yan, Fangrong, Sumithra J. Mandrekar, & Ying Yuan. (2017). Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research. 23(15). 3994–4003. 108 indexed citations
19.
Yan, Fangrong, Peter F. Thall, K.H. Lu, Mark R. Gilbert, & Ying Yuan. (2017). Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding. Annals of Oncology. 29(3). 694–699. 62 indexed citations
20.
Yan, Fangrong, et al.. (2014). Parameter Estimation of Population Pharmacokinetic Models with Stochastic Differential Equations: Implementation of an Estimation Algorithm. Journal of Probability and Statistics. 2014. 1–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dinesh P. de Alwis Breakdown of academic impact, for papers by Alexei Dmitrienko Breakdown of academic impact, for papers by Jin Y. Jin Breakdown of academic impact, for papers by Frank Pétavy Breakdown of academic impact, for papers by Tomoyuki Sugimoto Breakdown of academic impact, for papers by Robert Gagnon Breakdown of academic impact, for papers by Mark Sale Breakdown of academic impact, for papers by Ji Lin Breakdown of academic impact, for papers by Ivan Nestorov
Rankless by CCL
2026